CM-AT is based on research that showed enzyme deficiencies in autistic children, resulting in an inability to digest protein. The inability to digest protein affects the production of amino acids, the building blocks of chemicals essential for brain function.
The company claims that CM-AT will be one of the first therapies to address the underlying physiology of autism.
Joan Fallon, founder and CEO of Curemark, said: “We have six new trial sites that are now active and recruiting patients, New York, Philadelphia, Houston, Indianapolis, Columbus and Shreveport. These are in addition to the four that we announced had opened enrollment in October and November. We’re moving very rapidly with our clinical trial program and anticipate that the remaining sites will be initiating enrollment soon.
“We’re hopeful about the viability of Curemark’s enzyme replacement therapy and the promise of CM-AT in targeting the physiology of autism for the first time.”